Welcome to our dedicated page for ESTABLISHMENT LABS HOLDINGS SEC filings (Ticker: ESTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Establishment Labs Holdings Inc. filings document regulatory disclosures for a British Virgin Islands medical technology issuer listed on Nasdaq. Its Form 8-K reports cover operating results and financial condition, preliminary financial information, Regulation FD presentation materials, credit-agreement amendments, senior secured term-loan obligations, and other material definitive agreements.
The company’s proxy materials disclose board matters, executive compensation, equity awards, shareholder voting items, and governance practices. Together, the filings describe the Motiva-focused breast aesthetics and reconstruction business, capital structure, debt arrangements, forward-looking-statement disclosures, and recurring corporate reporting obligations.
Capital Research Global Investors reports beneficial ownership of 1,024,417 shares of Establishment Labs Holdings Inc., equal to 3.5% of 28,917,254 shares outstanding. The filing states that CRGI is a division of Capital Research and Management Company and related investment management entities that provide services under the name "Capital Research Global Investors." CRGI reports sole voting power and sole dispositive power over the 1,024,417 shares.
The filing further certifies the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The filing is categorized as an investment adviser (Type: IA).
ESTABLISHMENT LABS HOLDINGS INC. director Lewin Nicholas Sheridan reported an open-market purchase of 2,300 common shares at an average price of $34.2955 per share. The newly purchased shares are held indirectly through his spouse. Following this transaction, he reports direct ownership of 1,075,923 common shares and an additional 16,490 shares held indirectly.
Filippo Caldini, who is listed as Chief Executive Officer and a director of Establishment Labs Holdings Inc. (ESTA), reported a purchase of common shares on 08/11/2025. The amended Form 4/A shows a purchase of 2,850 common shares at $35.20 per share, resulting in reported beneficial ownership of 35,245 shares. The transaction is reported with code P and the ownership is listed as direct (D).
The filing is an amendment (Form 4/A) submitted by a single reporting person and was signed on behalf of the reporting person by Rajbir S. Denhoy, Chief Financial Officer, by power of attorney. The document does not state total outstanding shares or the percentage that 35,245 shares represent, so the filing alone does not establish the transaction's materiality to shareholders.
Establishment Labs Holdings insider Filippo Caldini, who serves as both Chief Executive Officer and a director, reported purchases of 2,850 common shares of the company on 08/11/2025. The Form 4 shows a weighted average purchase price of $35.2 and reports total direct beneficial ownership after the transaction of 35,245 shares. The filing states the trades were executed in multiple transactions at prices ranging from $34.00 to $35.00 and that the reporting person will provide a full breakdown of shares purchased at each price upon request. No derivative securities were reported.